COMPARATIVE EFFECTIVENESS OF GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF) FOR REDUCING INCIDENCE OF FEBRILE NEUTROPENIA (FN) -RELATED HOSPITALIZATION: A RETROSPECTIVE COHORT STUDY USING GERMAN CLAIMS DATA

被引：3

作者：

Wetten, S. ^{[1
]}

Li, X. ^{[2
]}

Haas, J. ^{[3
]}

Worth, G. ^{[4
]}

Jacob, C. ^{[3
]}

Braun, S. ^{[3
]}

Tzivelekis, S. ^{[2
]}

机构：

[1] Amgen Ltd, Uxbridge, Middx, England

[2] Amgen Inc, Thousand Oaks, CA 91320 USA

[3] Xcenda GmbH, Hannover, Germany

[4] Amgen Ltd, Zug, Switzerland

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 07期

关键词：

D O I：

10.1016/j.jval.2015.09.1042

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN27

引用

页码：A434 / A434

页数：1

共 45 条

[31] Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study
Jin Seok Kim
Dok Hyun Yoon
Seonyang Park
Sung-Soo Yoon
Seok-Goo Cho
Chang-Ki Min
Je-Jung Lee
Deok-Hwan Yang
Jae-Yong Kwak
Hyeon-Seok Eom
Won Seog Kim
Hawk Kim
Young Rok Do
Joon Ho Moon
Jihye Lee
Cheolwon Suh
Annals of Hematology, 2016, 95 : 603 - 611
[32] COST-EFFECTIVENESS OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH STAGES 2 AND 3 BREAST CANCER (BC) UNDERGOING CYTOTOXIC CHEMOTHERAPY IN FRANCE
Perrier, L.
Bachelot, T.
Leon, N.
Maurel, F.
Cohen-Nizard, S.
De Liege, F.
De Liege, F.
VALUE IN HEALTH, 2011, 14 (07) : A448 - A448
[33] PROSPECTIVE AND RANDOMIZED STUDY OF FIXED VS FLEXIBLE SCHEDULE OF POST CHEMOTHERAPY ADMINISTRATION OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF): PRELIMINARY DATA
Yankelevich, M.
Henry, M.
Bhambhani, K.
Taub, J. W.
PEDIATRIC BLOOD & CANCER, 2014, 61 : S404 - S405
[34] Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations
Aapro, M.
Boccia, R.
Choquet, S.
Hus, I.
Link, H.
Sliwa, T.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S167 - S167
[35] Febrile Neutropenia (FN) in Early Breast Cancer Patients Receiving FEC-D - the Effect of Moving to Primary Granulocyte-colony Stimulating Factor (G-CSF) in the Mersey and Cheshire Cancer Network
Mullard, A. P.
O'Reilly, S. M.
Ali, Z.
Schofield, P. S.
Malik, Z. M.
Wong, H. C.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : S177 - S178
[36] Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN-risk chemotherapy (chemo).
Blayney, Douglas W.
Joyner, Alice Kate Cummings
Jarvis, John
Nunag, Dominic
Wells, Jasmine
Huang, Lan
Mohanlal, Ramon W.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[37] Prevention of chemotherapy-induced febrile neutropenia (FN) by antibiotics (AB) versus antibiotics plus granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC): A randomized phase III study.
Timmer-Bonte, J
Biesma, B
Smit, J
Wilschut, F
Akkermans, J
De Boo, T
Bootsma, G
Tjan-Heijnen, VC
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 729S - 729S
[38] ECONOMIC MODEL OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE NEUTROPENIA (FN) IN NON-HODGKIN'S LYMPHOMA (NHL) PATIENTS UNDERGOING CHEMOTHERAPY IN FRANCE
Perrier, L.
Sebban, C.
Leon, N.
Maurel, F.
Cohen-Nizard, S.
De Liege, F.
VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
[39] Prevention of chemotherapy-induced febrile neutropenia (FN) by the addition of granulocyte-colony stimulating factor (G-CSF) to antibiotics in small cell lung cancer (SCLC) patients at risk of FN: A prospective economic evaluation along a Dutch randomised phase III trial
Timmer-Bonte, J
Adang, E
de Boo, T
Tjan-Heijnen, V
LUNG CANCER, 2005, 49 : S342 - S343
[40] The economic implications of adding granulocyte-colony stimulating factor (G-CSF) and/or antibiotics as secondary prophylaxis to small cell lung cancer (SCLC) patients at risk of febrile neutropenia (FN): A Markov model based on the clinical results of a prospective randomised phase III study
Timmer-Bonte, J
Termeer, E
Adang, E
Tjan-Heijnen, V
LUNG CANCER, 2005, 49 : S343 - S343

← 1 2 3 4 5 →